Equities

ASKA Pharmaceutical Holdings Co Ltd

ASKA Pharmaceutical Holdings Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)2,399.00
  • Today's Change117.00 / 5.13%
  • Shares traded100.80k
  • 1 Year change+84.97%
  • Beta1.3199
Data delayed at least 20 minutes, as of Jun 14 2024 07:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

ASKA Pharmaceutical Holdings Co Ltd is a Japan-based company mainly engaged in the pharmaceutical business. The Company mainly operates in two business segments. The Pharmaceutical segment is mainly engaged in the manufacture, purchase and sale of pharmaceutical products. The Others segment is involved in the manufacture of veterinary drugs, the provision of clinical testing services, the outsourcing of testing services, the purchase and sale of medical equipment, as well as the sale of health foods.

  • Revenue in JPY (TTM)62.84bn
  • Net income in JPY7.55bn
  • Incorporated2021
  • Employees747.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Seikagaku Corp36.21bn2.19bn47.10bn976.0020.680.625812.091.3040.0840.08663.801,324.810.46012.065.02--2.780.42613.050.467846.6054.186.040.98144.47--0.0055415.528.244.99-2.24-0.522430.280.00
SanBio Co Ltd0.00-2.16bn53.19bn29.00--22.16-----32.93-32.930.0034.970.00----0.00-41.79-42.00-48.20-48.88-------4,790.72----0.1995------52.44--53.94--
Shin Nippon Biomedical Laboratories Ltd26.45bn5.53bn58.08bn1.21k10.501.7011.312.20132.86132.86635.35819.430.39611.245.08--8.2610.5412.4315.9354.0052.7320.8625.320.7835--0.433924.215.4211.05-8.7323.1850.9075.54
ispace Inc2.36bn-2.37bn67.99bn216.00--6.98--28.84-31.36-31.3629.06104.640.13777.4898.55---13.83---24.15--39.38---100.39--2.05--0.5623--138.27--79.24------
Cuorips Inc23.10m-632.18m68.13bn46.00--11.37--2,948.98-86.04-86.043.14752.260.00474.6617.57---12.94---13.30--41.69---2,736.49--33.80-------39.65---39.84------
ASKA Pharmaceutical Holdings Co Ltd62.84bn7.55bn73.32bn747.009.001.108.581.17266.48266.482,219.592,186.080.70661.694.08--8.484.6311.085.8748.8046.9412.016.761.49--0.132814.423.946.1278.0334.04-37.8923.36
Katakura Industries Co., Ltd.39.83bn3.01bn73.95bn1.04k23.100.902312.561.8690.9090.901,203.272,327.460.28582.354.4938,300,000.002.292.352.993.3438.3037.758.018.322.58--0.109718.8116.62-2.048.0918.87-7.4610.76
JCR Pharmaceuticals Co Ltd42.87bn5.51bn76.13bn879.0013.371.3010.231.7843.9143.91342.28450.130.43490.58913.29--5.628.668.4713.4672.9074.5112.9218.241.2227.690.292129.6024.8313.1146.008.1918.5421.67
Eiken Chemical Co Ltd40.05bn2.63bn79.67bn754.0029.311.5618.641.9970.5270.521,080.891,328.720.62622.833.40--4.128.015.0610.1441.7645.926.5811.502.62--0.086235.21-7.442.29-54.08-5.2411.6611.20
Torii Pharmaceutical Co Ltd56.28bn5.29bn104.26bn583.0019.250.854718.151.85188.05188.052,002.444,235.560.42882.722.2596,531,740.004.036.524.447.3544.8349.559.4017.985.58--0.0024.1711.74-2.674.4428.76-20.3820.11
Kyorin Pharmaceutical Co Ltd119.53bn5.32bn108.74bn2.14k18.160.739312.720.909792.7092.702,082.822,276.510.67591.342.61--3.013.053.903.7943.0147.114.454.761.45--0.13866.815.531.0212.68-4.987.41-7.06
Mochida Pharmaceutical Co Ltd102.89bn4.55bn109.49bn1.53k23.130.809516.841.06126.33126.332,868.813,609.640.64781.863.28--2.864.373.445.3150.6152.474.426.713.31----44.88-0.3641-1.26-31.61-11.6310.91-1.21
Data as of Jun 14 2024. Currency figures normalised to ASKA Pharmaceutical Holdings Co Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

12.41%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 09 May 2024708.20k2.32%
Dimensional Fund Advisors LPas of 30 Apr 2024658.92k2.16%
Nomura Asset Management Co., Ltd.as of 30 Apr 2024629.00k2.06%
Amundi Japan Ltd.as of 30 Apr 2024418.80k1.37%
Dalton Investments, Inc.as of 08 Apr 2024368.80k1.21%
Nikko Asset Management Co., Ltd.as of 10 May 2024336.50k1.10%
Daiwa Asset Management Co. Ltd.as of 30 Apr 2024286.30k0.94%
Mitsubishi UFJ Asset Management Co., Ltd.as of 12 Dec 2022171.80k0.56%
Norges Bank Investment Managementas of 31 Dec 2023162.30k0.53%
BlackRock Japan Co. Ltd.as of 09 May 202453.50k0.18%
More ▼
Data from 31 Dec 2023 - 27 May 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.